Reviewer's report
Title:Association between ERCC1 and TS expression levels and disease free
survival in colorectal cancer patients in response to oxaliplatin and fluorouracil
(5-FU) adjuvant chemotherapy
Version:1Date:7 March 2014
Reviewer: Ida Hilmi
Reviewer's report:
The subject matter is an interesting one. However, I think major compulsory
revisions have to be made.
The major flaw is the methodology. the authors seem to be looking at too many
things; is the study trying to test a new regime (chemo 2) with higher oxaliplatin
dose, to look for ERCC1 and TS expression level in DFS or to look at the
correlation between these markers and response to oxaliplatin? If the last aim is
the major one, I don't think this was clearly demonstrated at all. A comparison
would have to be made between two matched groups using a standardized
oxaliplatin based regimen and then comparing the expression levels between the
two groups.
Minor Revisions
The conclusion topic was inserted wrongly, should only be before the last
concluding paragraph.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
'I declare that I have no competing interests
Reviewer's report
Title:Association between ERCC1 and TS expression levels and disease free
survival in colorectal cancer patients in response to oxaliplatin and fluorouracil
(5-FU) adjuvant chemotherapy
Version:1Date:7 March 2014
Reviewer: Ida Hilmi
Reviewer's report:
The subject matter is an interesting one. However, I think major compulsory
revisions have to be made.
The major flaw is the methodology. the authors seem to be looking at too many
things; is the study trying to test a new regime (chemo 2) with higher oxaliplatin
dose, to look for ERCC1 and TS expression level in DFS or to look at the
correlation between these markers and response to oxaliplatin? If the last aim is
the major one, I don't think this was clearly demonstrated at all. A comparison
would have to be made between two matched groups using a standardized
oxaliplatin based regimen and then comparing the expression levels between the
two groups.
Minor Revisions
The conclusion topic was inserted wrongly, should only be before the last
concluding paragraph.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
'I declare that I have no competing interests
Please review this paper.
user
Reviewer's report
Title:Association between ERCC1 and TS expression levels and disease free
survival in colorectal cancer patients in response to oxaliplatin and fluorouracil
(5-FU) adjuvant chemotherapy
Version:1Date:7 March 2014
Reviewer: Ida Hilmi
Reviewer's report:
The subject matter is an interesting one. However, I think major compulsory
revisions have to be made.
The major flaw is the methodology. the authors seem to be looking at too many
things; is the study trying to test a new regime (chemo 2) with higher oxaliplatin
dose, to look for ERCC1 and TS expression level in DFS or to look at the
correlation between these markers and response to oxaliplatin? If the last aim is
the major one, I don't think this was clearly demonstrated at all. A comparison
would have to be made between two matched groups using a standardized
oxaliplatin based regimen and then comparing the expression levels between the
two groups.
Minor Revisions
The conclusion topic was inserted wrongly, should only be before the last
concluding paragraph.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
'I declare that I have no competing interests
assistant